Reporting and impact of subsequent cycle toxicities in oncology phase I clinical trials.

Avina Rami Steven G DuBoisKevin Campbell

Published in: Clinical trials (London, England) (2023)

Reporting of subsequent cycle toxicity is uncommon in oncology phase I clinical trial publications and becoming less common over time. Guidelines for reporting of phase I oncology clinical trials should expand to include toxicity data beyond the first cycle.

Keyphrases

clinical trial
palliative care
adverse drug
phase ii
oxidative stress
open label
double blind
study protocol
electronic health record
phase iii
emergency department
big data
artificial intelligence
oxide nanoparticles